Tag: DK0060257814

news source FOR company information content 1 market releases

Zealand Pharma – Transactions related to share buy-back program (week 23, 2026)

Company announcement No. 23 / 2026

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Press release – No. 13 / 2026

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 17 / 2025

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

Company announcement – No. 16 / 2025

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 14 / 2025

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsDK0060257814